P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 4, 2004, Pages 1073-1081

  Sankatsing, Sanjay U C ^a,b   Beijnen, Jos H ^c   Schinkel, Alfred H ^d   Lange, Joep M A ^a,b   Prins, Jan M ^a,e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Intl Antiviral Ther Eval Center   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOCHROME P450 3A4; DOMPERIDONE; GLYCOPROTEIN P; LOPERAMIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CELL ACTIVITY; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG TRANSPORT; GENETIC POLYMORPHISM; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; SHORT SURVEY; SMALL INTESTINE; T LYMPHOCYTE; TESTIS; VIRUS REPLICATION;

ANTI-HIV AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HIV INFECTIONS; HIV-1; HUMANS; P-GLYCOPROTEIN; VIRUS REPLICATION;

EID: 1642420430     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.4.1073-1081.2004     Document Type: Short Survey

References (154)

1. Alaoui-Jamali, M. A., R. L. Schecter, Y. M. Rustum, M. G. Centurioni, S. Lehnert, and G. Batist. 1993. In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933. J. Pharmacol. Exp. Ther. 264:1299-1304.
2. Ameyaw, M. M., F. Regateiro, T. Li, X. Liu, M. Tariq, A. Mobarek, N. Thornton, G. O. Folayan, J. Githang'a, A. Indalo, D. Ofori-Adjei, D. A. Price-Evans, and H. L. McLeod. 2001. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11:217-221.
3. + T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retrovir. 12:1457-1462.
4. Antonelli, G., O. Turriziani, M. Cianfiriglia, E. Riva, G. Dong, A. Fattorossi, and F. Dianzani. 1992. Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. AIDS Res. Hum. Retrovir. 8:1839-1844.
5. Barry, M., F. Mulcahy, C. Merry, S. Gibbons, and D. Back. 1999. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin. Pharmacokinet. 36:289-304.
6. Beaulieu, E., M. Demeule, L. Ghitescu, and R. Beliveau. 1997. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem. J. 326(Pt 2):539-544.
7. Belpomme, D., S. Gauthier, E. Pujade-Lauraine, T. Facchini, M. J. Goudier, I. Krakowski, G. Netter-Pinon, M. Frenay, C. Gousset, F. N. Marie, M. Benmiloud, and F. Sturtz. 2000. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann. Oncol. 11:1471-1476.
8. Boesch, D., K. Muller, A. Pourtier-Manzanedo, and F. Loor. 1991. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell Res. 196:26-32.
9. Borst, P., and A. H. Schinkel. 1996. What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur. J. Cancer 32A:985-990.
10. Borst, P., A. H. Schinkel, J. J. Smit, E. Wagenaar, L. Van Deemter, A. J. Smith, E. W. Eijdems, F. Baas, and G. J. Zaman. 1993. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol. Ther. 60:289-299.
11. Brenner, B. G., A. Dascal, R. G. Margolese, and M. A. Wainberg. 1989. Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases. J. Leukoc. Biol. 46:75-83.
12. Brinkmann, U., and M. Eichelbaum. 2001. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J. 1:59-64.
13. Bruggemann, E. P., U. A. Germann, M. M. Gottesman, and I. Pastan. 1989. Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine. J. Biol. Chem. 264:15483-15488.
14. Callaghan, R., G. Berridge, D. R. Ferry, and C. F. Higgins. 1997. The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface. Biochim. Biophys. Acta 1328:109-124.
15. Chaillou, S., J. Durant, R. Garraffo, E. Georgenthum, C. Roptin, B. Dunais, V. Mondain, P. M. Roger, and P. Dellamonica. 2002. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin. Trials 3:493-501.
16. Chang, K. H., J. M. Kim, N. C. Yoo, W. H. Kim, J. H. Park, I. H. Choi, H. S. Kim, K. W. Lee, Y. G. Song, S. K. Hong, and H. Y. Kim. 2000. Restoration of P-glycoprotein function is involved in the increase of natural killer activity with exogenous interleukin-15 in human immunodeficiency virus-infected individuals. Yonsei Med. J. 41:600-606.
17. Chaudhary, P. M., E. B. Mechetner, and I. B. Roninson. 1992. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80:2735-2739.
18. Chaudhary, P. M., and I. B. Roninson. 1991. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85-94.
19. Chauffert, B., M. Martin, A. Hammann, M. F. Michel, and F. Martin. 1986. Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res. 46:825-830.
20. Chauffert, B., D. Rey, B. Coudert, M. Dumas, and F. Martin. 1987. Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumour cells. Br. J. Cancer 56:119-122.
21. Chong, A. S., P. N. Markham, H. M. Gebel, S. D. Bines, and J. S. Coon. 1993. Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol. Immunother. 36:133-139.
22. Choo, E. F., B. Leake, C. Wandel, H. Imamura, A. J. Wood, G. B. Wilkinson, and R. B. Kim. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28:655-660.
23. Chun, T. W., L. Carruth, D. Finzi, X. Shen, J. A. DiGiuseppe, H. Taylor, M. Hermankova, K. Chadwick, J. Margolick, T. C. Quinn, Y. H. Kuo, B. Brookmeyer, M. A. Zeiger, P. Barditch-Crovo, and B. F. Siliciano. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
24. Chun, T. W., L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. Mican, M. Baseler, A. L. Lloyd, M. A. Nowak, and A. S. Fauci. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94:13193-13197.
25. Clayette, P., S. Jorajuria, and D. Dormont. 2000. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 14:235-236.
26. Cordon-Cardo, C., J. P. O'Brien, D. Casals, L. Rittman-Grauer, J. L. Biedler, M. R. Melamed, and J. B. Bertino. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86:695-698.
27. Cornwell, M. M., M. M. Gottesman, and I. H. Pastan. 1986. Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J. Biol. Chem. 261:7921-7928.
28. Dale, I. L., W. Tuffley, R. Callaghan, J. A. Holmes, K. Martin, M. Luscombe, P. Mistry, H. Ryder, A. J. Stewart, P. Charlton, P. B. Twentyman, and P. Bevan. 1998. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br. J. Cancer 78: 885-892.
29. Dantzig, A. H., B. L. Shepard, J. Cao, K. L. Law, W. J. Ehlhardt, T. M. Baughman, T. F. Bumol, and J. J. Starling. 1996. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56:4171-4179.
30. Detels, R., A. Munoz, G. McFarlane, L. A. Kingsley, J. B. Margolick, J. Giorgi, L. K. Schrager, J. P. Phair, et al. 1998. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 280:1497-1503.
31. Dey, S., M. Ramachandra, I. Pastan, M. M. Gottesman, and S. V. Ambudkar. 1997. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. Natl. Acad. Sci. USA 94:10594-10599.
32. Donahue, J. P., D. Dowdy, K. K. Ratnam, T. Hulgan, J. Price, D. Unutmaz, J. Nicotera, S. Raffanti, M. Becker, and D. W. Haas. 2003. Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Clin. Pharmacol. Ther. 73:78-86.
33. Dornadula, G., H. Zhang, B. VanUitert, J. Stern, L. Livornese, M. J. Ingerman, J. Witek, B. J. Kedanis, J. Natkin, J. DeSimone, and B. J. Pomerantz. 1999. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282:1627-1632.
34. Dresser, G. K., J. D. Spence, and D. G. Bailey. 2000. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38:41-57.
35. Drewe, J., H. Gutmann, G. Fricker, M. Torok, C. Beglinger, and J. Huwyler. 1999. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem. Pharmacol. 57:1147-1152.
36. Durr, D., B. Stieger, G. A. Kullak-Ublick, K. M. Rentsch, H. C. Steinert, P. J. Meier, and K. Fattinger. 2000. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68:598-604.
37. Eagling, V. A., D. J. Back, and M. G. Barry. 1997. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol. 44:190-194.
38. Edwards, J. E., K. R. Brouwer, and P. J. McNamara. 2002. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrob. Agents Chemother. 46:2284-2286.
39. Eisenbraun, M. D., and B. A. Miller. 1999. mdr1a-encoded P-glycoprotein is not required for peripheral T cell proliferation, cytokine release, or cytotoxic effector function in mice. J. Immunol. 163:2621-2627.
40. Erickson, D. A., G. Mather, W. F. Trager, R. H. Levy, and J. J. Keirns. 1999. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab. Dispos. 27:1488-1495.
41. Fellay, J., C. Marzolini, E. R. Meaden, D. J. Back, T. Buclin, J. P. Chave, L. A. Decosterd, H. Furrer, M. Opravil, G. Pantaleo, D. Retelska, L. Ruiz, A. H. Schinkel, P. Vernazza, C. B. Eap, and A. Telenti. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36.
42. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, B. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, B. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and B. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
43. Fitzsimmons, M. E., and J. M. Collins. 1997. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab. Dispos. 25:256-266.
44. Fojo, A. T., K. Ueda, D. J. Slamon, D. G. Poplack, M. M. Gottesman, and I. Pastan. 1987. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA 84:265-269.
45. Furtado, M. R., D. S. Callaway, J. P. Phair, K. J. Kunstman, J. L. Stanton, C. A. Macken, A. S. Perelson, and S. M. Wolinsky. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. Engl. J. Med. 340:1614-1622.
46. Ganapathhi, R., and D. Grabowsi. 1983. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by calmodulin inhibitor trifluoperazine. Cancer Res. 43:3696-3699.
47. Garrigos, M., L. M. Mir, and S. Orlowski. 1997. Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase-further experimental evidence for a multisite model. Eur. J. Biochem. 244:664-673.
48. Germann, U. A., D. Shlyakhter, V. S. Mason, R. E. Zelle, J. P. Duffy, V. Galullo, D. M. Armistead, J. O. Saunders, J. Boger, and M. W. Harding. 1997. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8:125-140.
49. Gollapudi, S., and S. Gupta. 1990. Human immunodeficiency virus 1-induced expression of P-glycoprotein. Biochem. Biophys. Res. Commun. 171: 1002-1007.
50. Gottesman, M. M., and I. Pastan. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385-427.
51. Greenberger, L. M., C. J. Lisanti, J. T. Silva, and S. B. Horwitz. 1991. Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded by mouse mdr1b. J. Biol. Chem. 266:20744-20751.
52. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
53. Gupta, S., and S. Gollapudi. 1993. P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. J. Clin. Immunol. 13:289-301.
54. + T cells: a role in cytotoxic effector function. J. Clin. Immunol. 12:451-458.
55. Gutmann, H., G. Fricker, J. Drewe, M. Toeroek, and D. S. Miller. 1999. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol. Pharmacol. 56:383-389.
56. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, J. E. Feinberg, H. H. Balfour, L. R. Deyton, J. A. Chodakewitz, M. A. Fischl, et al. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
57. Hennessy, M., D. Kelleher, J. P. Spiers, M. Barry, P. Kavanagh, D. Back, F. Mulcahy, and J. Feely. 2002. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br. J. Clin. Pharmacol. 53:75-82.
58. Higgins, C. F., and M. M. Gottesman. 1992. Is the multidrug transporter a flippase? Trends Biochem. Sci. 17:18-21.
59. Hochman, J. H., M. Chiba, J. Nishime, M. Yamazaki, and J. H. Lin. 2000. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J. Pharmacol. Exp. Ther. 292:310-318.
60. Hoffmeyer, S., O. Burk, O. von Richter, H. P. Arnold, J. Brockmoller, A. Johne, I. Cascorbi, T. Gerloff, I. Roots, M. Eichelbaum, and U. Brinkmann. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97:3473-3478.
61. Holash, J. A., and P. A. Stewart. 1993. The relationship of astrocyte-like cells to the vessels that contribute to the blood-ocular barriers. Brain Res. 629:218-224.
62. Hollt, V., M. Kouba, M. Dietel, and G. Vogt. 1992. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem. Pharmacol. 43:2601-2608.
63. Homolya, L., Z. Hollo, U. A. Germann, I. Pastan, M. M. Gottesman, and B. Sarkadi. 1993. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 268:21493-21496.
64. Huisman, M. T., J. W. Smit, K. M. Crummentuyn, N. Zelcer, H. B. Wiltshire, J. H. Beijnen, and A. H. Schinkel. 2002. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16:2295-2301.
65. Huisman, M. T., J. W. Smit, H. R. Wiltshire, J. H. Beijnen, and A. H. Schinkel. 2003. Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir. J. Pharmacol. Exp. Ther. 304:596-602.
66. Huisman, M. T., J. W. Smit, H. R. Wiltshire, R. M. Hoetelmans, J. H. Beijnen, and A. H. Schinkel. 2001. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 59:806-813.
67. Hyafil, F., C. Vergely, V. P. Du, and T. Grand-Perret. 1993. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:4595-4602.
68. Jones, K., P. G. Bray, S. H. Khoo, R. A. Davey, E. R. Meaden, S. A. Ward, and D. J. Back. 2001. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 15:1353-1358.
69. Jones, K., P. G. Hoggard, S. D. Sales, S. Khoo, R. Davey, and D. J. Back. 2001. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 15:675-681.
70. Jonker, J. W., J. W. Smit, R. F. Brinkhuis, M. Maliepaard, J. H. Beijnen, J. H. Schellens, and A. H. Schinkel. 2000. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92:1651-1656.
71. Juliano, R. L., and V. Ling. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152-162.
72. Katoh, M., M. Nakajima, H. Yamazaki, and T. Yokoi. 2001. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur. J. Pharm. Sci. 12:505-513.
73. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
74. Kim, A. E., J. M. Dintaman, D. S. Waddell, and J. A. Silverman. 1998. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J. Pharmacol. Exp. Ther. 286:1439-1445.
75. Kim, R. B., M. F. Fromm, C. Wandel, B. Leake, A. J. Wood, D. M. Roden, and G. R. Wilkinson. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Investig. 101:289-294.
76. Kim, R. B., B. F. Leake, E. F. Choo, G. K. Dresser, S. V. Kubba, U. I. Schwarz, A. Taylor, H. G. Xie, J. McKinsey, S. Zhou, L. B. Lan, J. D. Schuetz, E. G. Schuetz, and G. R. Wilkinson. 2001. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70:189-199.
77. Koudriakova, T., E. Iatsimirskaia, I. Utkin, E. Gangl, P. Vouros, E. Storozhuk, D. Orza, J. Marinina, and N. Gerber. 1998. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos. 26:552-561.
78. Krishna, R., and L. D. Mayer. 2000. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11:265-283.
79. Kumar, G. N., J. Dykstra, E. M. Roberts, V. K. Jayanti, D. Hickman, J. Uchic, Y. Yao, B. Surber, S. Thomas, and G. R. Granneman. 1999. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab. Dispos. 27:902-908.
80. Kurata, Y., I. Ieiri, M. Kimura, T. Morita, S. Irie, A. Urae, S. Ohdo, H. Ohtani, Y. Sawada, S. Higuchi, and K. Otsubo. 2002. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. 72:209-219.
81. Lankas, G. R., L. D. Wise, M. E. Cartwright, T. Pippert, and D. R. Umbenhauer. 1998. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. 12:457-463.
82. Lee, C. G., M. M. Gottesman, C. O. Cardarelli, M. Ramachandra, K. T. Jeang, S. V. Ambudkar, I. Pastan, and S. Dey. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
83. Lee, C. G., M. Ramachandra, K. T. Jeang, M. A. Martin, I. Pastan, and M. M. Gottesman. 2000. Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J. 14:516-522.
84. Lee, L. M., J. M. Karon, R. Selik, J. J. Neal, and P. L. Fleming. 2001. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 285:1308-1315.
85. List, A. F., K. J. Kopecky, C. L. Willman, D. R. Head, D. L. Persons, M. L. Slovak, R. Dorr, C. Karanes, H. E. Hynes, J. H. Doroshow, M. Shurafa, and F. R. Appelbaum. 2001. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98:3212-3220.
86. Lucia, M. B., R. Cauda, A. L. Landay, W. Malorni, G. Donelli, and L. Ortona. 1995. Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function. AIDS Res. Hum. Retrovir. 11:893-901.
87. Lucia, M. B., R. Cauda, W. Malorni, G. Rainaldi, M. Tumbarello, E. Tacconelli, C. Rumi, G. Donelli, and L. Ortona. 1995. P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients. Immunol. Lett. 47:223-226.
88. Lucia, M. B., S. Rutella, G. Leone, L. M. Larocca, S. Vella, and R. Cauda. 2002. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. J. Acquir. Immune Defic. Syndr. 30:369-378.
89. Ludescher, C., G. Pall, E. U. Irschick, and G. Gastl. 1998. Differential activity of P-glycoprotein in normal blood lymphocyte subsets. Br. J. Haematol. 101:722-727.
90. Mayer, U., E. Wagenaar, B. Dorobek, J. H. Beijnen, P. Borst, and A. H. Schinkel. 1997. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Investig. 100:2430-2436.
91. Meaden, E. R., P. G. Hoggard, B. Maher, S. H. Khoo, and D. J. Back. 2001. Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res. Hum. Retrovir. 17:1329-1332.
92. Meaden, E. R., P. G. Hoggard, P. Newton, J. F. Tjia, D. Aldam, D. Cornforth, J. Lloyd, I. Williams, D. J. Back, and S. H. Khoo. 2002. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J. Antimicrob. Chemother. 50:583-588.
93. Meissner, K., B. Sperker, C. Karsten, H. M. Zu Schwabedissen, U. Seeland, M. Bohm, S. Bien, P. Dazert, C. Kunert-Keil, S. Vogelgesang, B. Warzok, W. Siegmund, I. Cascorbi, M. Wendt, and H. K. Kroemer. 2002. Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J. Histochem. Cytochem. 50:1351-1356.
94. Miller, D. S., S. N. Nobmann, H. Gutmann, M. Toeroek, J. Drewe, and G. Fricker. 2000. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol. Pharmacol. 58:1357-1367.
95. Millward, M. J., B. M. Cantwell, N. C. Munro, A. Robinson, P. A. Corris, and A. L. Harris. 1993. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br. J. Cancer 67:1031-1035.
96. Mocroft, A., S. Vella, T. L. Benfield, A. Chiesi, V. Miller, P. Gargalianos, M. A. d'Arminio, I. Yust, J. N. Bruun, A. N. Phillips, J. D. Lundgren, et al. 1998. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 352:1725-1730.
97. Nakamura, Y., S. Ikeda, T. Furukawa, T. Sumizawa, A. Tani, S. Akiyama, and Y. Nagata. 1997. Function of P-glycoprotein expressed in placenta and mole. Biochem. Biophys. Res. Commun. 235:849-853.
98. Newman, M. J., J. C. Rodarte, K. D. Benbatoul, S. J. Romano, C. Zhang, S. Krane, E. J. Moran, R. T. Uyeda, B. Dixon, E. S. Guns, and L. D. Mayer. 2000. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 60:2964-2972.
99. Neyfakh, A. A. 1988. Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Exp. Cell Res. 174:168-176.
100. Nooter, K., R. Oostrum, R. Jonker, H. van Dekken, W. Stokdijk, and G. van den Engh. 1989. Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry. Cancer Chemother. Pharmacol. 23:296-300.
101. Olson, D. P., D. T. Scadden, B. T. D'Aquila, and M. P. De Pasquale. 2002. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS 16:1743-1747.
102. Palella, F. J., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Holmberg, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
103. Pirker, R., G. Keilhauer, M. Raschack, C. Lechner, and H. Ludwig. 1990. Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil. Int. J. Cancer 45:916-919.
104. Profit, L., V. A. Eagling, and D. J. Back. 1999. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13:1623-1627.
105. Ramachandra, M., S. V. Ambudkar, D. Chen, C. A. Hrycyna, S. Dey, M. M. Gottesman, and I. Pastan. 1998. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37: 5010-5019.
106. Raviv, Y., H. B. Pollard, E. P. Bruggemann, I. Pastan, and M. M. Gottesman. 1990. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem. 265:3975-3980.
107. Roepe, P. D. 1995. The role of the MDR protein in altered drug translocation across tumor cell membranes. Biochim. Biophys. Acta 1241:385-405.
108. Sakaeda, T., T. Nakamura, and K. Okumura. 2002. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull. 25: 1391-1400.
109. Sawchuk, R. J., and Z. Yang. 1999. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv. Drug Deliv. Rev. 39:5-31.
110. Schaeffeler, E., M. Eichelbaum, U. Brinkmann, A. Penger, S. Asante-Poku, U. M. Zanger, and M. Schwab. 2001. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358:383-384.
111. Schinkel, A. H., U. Mayer, E. Wagenaar, C. A. Mol, L. Van Deemter, J. J. Smit, M. A. van der Valk, A. C. Voordouw, H. Spits, O. van Tellingen, J. M. Zijlmans, W. E. Fibbe, and P. Borst. 1997. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA 94:4028-4033.
112. Schinkel,A. H., J. J. Smit, O. van Tellingen, J. H. Beijnen, E. Wagenaar, L. Van Deemter, C. A. Mol, M. A. van der Valk, E. C. Robanus-Maandag, and H. P. te Riele. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
113. Schinkel, A. H., E. Wagenaar, C. A. Mol, and L. Van Deemter. 1996. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Investig. 97: 2517-2524.
114. Schinkel, A. H., E. Wagenaar, L. Van Deemter, C. A. Mol, and P. Borst. 1995. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Investig. 96:1698-1705.
115. Schuetz, J. D., M. C. Connelly, D. Sun, S. G. Paibir, P. M. Flynn, R. V. Srinivas, A. Kumar, and A. Fridland. 1999. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5:1048-1051.
116. Schuurhuis, G. J., H. J. Broxterman, J. J. van der Hoeven, H. M. Pinedo, and J. Lankelma. 1987. Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. A comparison with verapamil. Cancer Chemother. Pharmacol. 20: 285-290.
117. Sharkey, M. E., I. Teo, T. Greenough, N. Sharova, K. Luzuriaga, J. L. Sullivan, R. P. Bucy, L. G. Kostrikis, A. Haase, C. Veryard, R. E. Davaro, S. H. Cheeseman, J. S. Daly, C. Bova, R. T. Ellison, B. Mady, K. K. Lai, G. Moyle, M. Nelson, B. Gazzard, S. Shaunak, and M. Stevenson. 2000. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 6:76-81.
118. Sharom, F. J., X. Yu, and C. A. Doige. 1993. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J. Biol. Chem. 268:24197-24202.
119. Shiraki, N., A. Hamada, K. Yasuda, J. Fujii, K. Arimori, and M. Nakano. 2000. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins. Biol. Pharm. Bull. 23:1528-1531.
120. Smit, J. W., M. T. Huisman, O. van Tellingen, H. R. Wiltshire, and A. H. Schinkel. 1999. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Investig. 104: 1441-1447.
121. Solary, E., I. Velay, B. Chauffert, J. M. Bidan, D. Caillot, M. Dumas, and H. Guy. 1991. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68:1714-1719.
122. Sparreboom, A., J. van Asperen, U. Mayer, A. H. Schinkel, J. W. Smit, D. K. Meijer, P. Borst, W. J. Nooijen, J. H. Beijnen, and O. van Tellingen. 1997. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94:2031-2035.
123. Speck, R. R., X. F. Yu, J. Hildreth, and C. Flexner. 2002. Differential effects of P-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J. Infect. Dis. 186:332-340.
124. Srinivas, R. V., D. Middlemas, P. Flynn, and A. Fridland. 1998. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob. Agents Chemother. 42:3157-3162.
125. Stein, W. D., C. Cardarelli, I. Pastan, and M. M. Gottesman. 1994. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol. Pharmacol. 45:763-772.
126. Stormer, E., L. L. von Moltke, M. D. Perloff, and D. J. Greenblatt. 2002. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm. Res. 19:1038-1045.
127. Tan, B., D. Piwnica-Worms, and L. Ratner. 2000. Multidrug resistance transporters and modulation. Curr. Opin. Oncol. 12:450-458.
128. Thiebaut, F., T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735-7738.
129. Thiebaut, F., T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. 1989. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a
130. Toffoli, G., F. Simone, G. Corona, M. Raschack, B. Cappelletto, M. Gigante, and M. Boiocchi. 1995. Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. Biochem. Pharmacol. 50:1245-1255.
131. Tsuruo, T., H. Iida, Y. Kitatani, K. Yokota, S. Tsukagoshi, and Y. Sakurai. 1984. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res. 44:4303-4307.
132. Tsuruo, T., H. Iida, M. Nojiri, S. Tsukagoshi, and Y. Sakurai. 1983. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 43:2905-2910.
133. Tsuruo, T., H. Iida, S. Tsukagoshi, and Y. Sakurai. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967-1972.
134. Tsuruo, T., H. Iida, S. Tsukagoshi, and Y. Sakurai. 1982. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 42:4730-4733.
135. Twentyman, P. R., N. E. Fox, and D. J. White. 1987. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br. J. Cancer 56:55-57.
136. Ueda, K., N. Okamura, M. Hirai, Y. Tanigawara, T. Saeki, N. Kioka, T. Komano, and R. Hori. 1992. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 267:24248-24252.
137. van Asperen, J., U. Mayer, O. van Tellingen, and J. H. Beijnen. 1997. The functional role of P-glycoprotein in the blood-brain barrier. J. Pharm. Sci. 86:881-884.
138. van Asperen, J., O. van Tellingen, and J. H. Beijnen. 1998. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol. Res. 37:429-435.
139. van der Sandt, C. J., C. M. Vos, L. Nabulsi, M. C. Blom-Roosemalen, H. H. Voorwinden, A. G. de Boer, and D. D. Breimer. 2001. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 15:483-491.
140. van Heeswijk, R. P., A. I. Veldkamp, R. M. Hoetelmans, J. W. Mulder, G. Schreij, A. Hsu, J. M. Lange, J. H. Beijnen, and P. L. Meenhorst. 1999. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 13:F95-F99.
141. van Praag, R. M., G. J. Weverling, P. Portegies, S. Jurriaans, X. J. Zhou, M. L. Turner-Foisy, J. P. Sommadossi, D. M. Burger, J. M. Lange, R. M. Hoetelmans, and J. M. Prins. 2000. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 14:1187-1194.
142. Vishnuvardhan, D., L. L. Moltke, C. Richert, and D. J. Greenblatt. 2003. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS 17:1092-1094.
143. von Moltke, L. L., D. J. Greenblatt, B. W. Granda, G. M. Giancarlo, S. X. Duan, J. P. Daily, J. S. Harmatz, and R. I. Shader. 2001. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J. Clin. Pharmacol. 41:85-91.
144. Wacher, V. J., C. Y. Wu, and L. Z. Benet. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. 13:129-134.
145. Wang, X., T. Furukawa, T. Nitanda, M. Okamoto, Y. Sugimoto, S. Akiyama, and M. Baba. 2003. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol. Pharmacol. 63:65-72.
146. Washington, C. B., H. R. Wiltshire, M. Man, T. Moy, S. R. Harris, E. Worth, P. Weigl, Z. Liang, D. Hall, L. Marriott, and T. F. Blaschke. 2000. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab. Dispos. 28:1058-1062.
147. Watkins, P. B. 1997. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27:161-170.
148. Wijnholds, J., C. A. Mol, L. Van Deemter, M. de Haas, G. L. Scheffer, F. Baas, J. H. Beijnen, R. J. Scheper, S. Hatse, E. De Clercq, J. Balzarini, and P. Borst. 2000. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. USA 97:7476-7481.
149. Williams, G. C., A. Liu, G. Knipp, and P. J. Sinko. 2002. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob. Agents Chemother. 46:3456-3462.
150. Wong, J. K., M. Hezareh, H. F. Gunthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
151. Yamaji, H., Y. Matsumura, Y. Yoshikawa, and K. Takada. 1999. Pharmacokinetic interactions between HIV-protease inhibitors in rats. Biopharm. Drug Dispos. 20:241-247.
152. Yamashiro, T., N. Watanabe, K. K. Yokoyama, C. Koga, T. Tsuruo, and Y. Kobayashi. 1998. Requirement of expression of P-glycoprotein on human natural killer leukemia cells for cell-mediated cytotoxicity. Biochem. Pharmacol. 55:1385-1390.
153. Yerly, S., L. Kaiser, T. V. Perneger, R. W. Cone, M. Opravil, J. P. Chave, H. Furrer, B. Hirschel, and L. Perrin. 2000. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS 14:243-249.
154. Zhang, Y., and L. Z. Benet. 2001. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 40:159-168.